We are live on ! Find out more
NEPH icon

Nephros
NEPH

19 hedge funds and large institutions have $4.94M invested in Nephros in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

25% more capital invested

Capital invested by funds: $3.95M → $4.94M (+$992K)

6% more funds holding

Funds holding: 18 → 19 (+1)

0.71% less ownership

Funds ownership: 42.05% → 41.34% (-0.71%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$10.4K
2
Citadel Advisors
Citadel Advisors
Florida
+$5.57K
3
MCC
Money Concepts Capital
Florida
+$53
4
Bank of America
Bank of America
North Carolina
+$15
5
Wells Fargo
Wells Fargo
California
+$2

Top Sellers

Rank Fund Capital Flow
1
BA
Bard Associates
Illinois
-$61.1K
2
VF
Virtu Financial
New York
-$16K
3
TSS
Two Sigma Securities
New York
-$9K
4
UBS Group
UBS Group
Switzerland
-$1.43K
5
TRCT
Tower Research Capital (TRC)
New York
-$1.19K
Name Holding Trade Value Shares
Change 		Change in
Stake
WC
1
Wexford Capital
Florida
$4.24M – – –
BA
2
Bard Associates
Illinois
$225K -$61.1K -57,335 -23%
Vanguard Group
3
Vanguard Group
Pennsylvania
$170K -$1.17K -1,098 -0.7%
HighTower Advisors
4
HighTower Advisors
Illinois
$64K – – –
EP
5
Elkhorn Partners
Nebraska
$58K – – –
William Blair & Company
6
William Blair & Company
Illinois
$41.9K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$37K +$10.4K +9,764 +44%
Citadel Advisors
8
Citadel Advisors
Florida
$20.5K +$5.57K +5,225 +40%
Morgan Stanley
9
Morgan Stanley
New York
$17.7K – – –
State Street
10
State Street
Massachusetts
$17.6K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$15K -$1.19K -1,114 -8%
UBS Group
12
UBS Group
Switzerland
$12.2K -$1.43K -1,343 -11%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$12K – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$5K – – –
BlackRock
15
BlackRock
New York
$4.78K – – –
Wells Fargo
16
Wells Fargo
California
$72 +$2 +2 +3%
MCC
17
Money Concepts Capital
Florida
$58 +$53 +50 New
Bank of America
18
Bank of America
North Carolina
$16 +$15 +14 New
VF
19
Virtu Financial
New York
– -$16K -17,089 Closed
TSS
20
Two Sigma Securities
New York
– -$9K -10,160 Closed
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
– +$1 +1 New

NEPH Hedge Fund Activity: Q4 2022 in Review

19 of the 6,224 institutional investors tracked by Wall St. Rank reported a position in Nephros (NEPH) for Q4 2022, worth a combined $4.94M — up 25% from $3.95M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new NEPH positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $10.4K. The largest seller was Bard Associates, cutting an estimated $61.1K.

  • 19 institutional investors held Nephros (NEPH) as of Q4 2022, up from 18 in Q3 2022.
  • Funds reported $4.94M of Nephros stock for Q4 2022, up 25% quarter-over-quarter.
  • 3 funds opened new Nephros positions in Q4 2022 and 2 closed out, a net change of +1 holder.
  • The largest Nephros buyer in Q4 2022 was Renaissance Technologies, an estimated $10.4K added.
  • The largest Nephros seller in Q4 2022 was Bard Associates, an estimated $61.1K sold.

Based on aggregated 13F filings for Q4 2022.